Chemoradiation therapy for esophageal cancer recurrence after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of chemoradiation therapy in patients with esophageal cancer who experience locoregional recurrence after radical or palliative surgery. It aims to address the high recurrence rates and lack of effective adjuvant therapies for these patients. The trial will utilize simultaneously integrated boost intensity-modulated radiation therapy (IMRT) combined with chemotherapy agents such as Paclitaxel and Platinum. The study will assess overall survival rates and optimal radiation doses based on previous retrospective data indicating improved outcomes with salvage chemoradiation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Locoregional recurrence after radical surgery;
* Positive resection margin (R1/R2) after surgery;
* Out-of-field recurrence after adjuvant chemoradiation or radiotherapy;
* Recurrence after adjuvant chemotherapy;
* No prior therapy after recurrence;
* Age 16-70 years;
* KPS\>70;
* No history of drug allergy;
* Sufficient liver and kidney functions;
* White blood cell count \> 4.0\*10\^9/L.

Exclusion Criteria:

* Age\>70 or \<16 years;
* Pregnancy or lactation;
* History of drug allergy;
* Declining informed consent;
* Insufficient liver or kidney functions, or abnormal CBC test;
* Severe cardiovascular diseases, infections, active ulcerations, diabetes mellitus with unstable blood sugar, mental disorders.

Where it's running

• Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Zefen Xiao, MD
• Email: xiaozefen@sina.com
• Phone: +86-13621018159

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.